

Special Issue

Novel Therapeutic Agents and Innovative Treatment Strategies Against Infectious Diseases

Message from the Guest Editor

This Special Issue focuses on innovative therapeutics for infectious diseases, with a particular emphasis on resistant and emerging pathogens. The rise of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) strains has heightened the need for novel therapies. We aim to highlight advancements in discovering new therapeutic agents, including small molecules, biologics, and vaccines, as well as innovative drug delivery systems like nanocarriers, lipid-based formulations, and targeted delivery strategies. The issue covers all microbial infections, with a focus on tuberculosis (TB), and explores novel molecular targets and host-targeted therapies to overcome microbial resistance and enhance therapeutic outcomes. It also examines new pathways in infectious disease pathogenesis, such as amino acid biosynthesis, host-microbe interactions, and viral replication processes, as potential targets for drug discovery. We invite original research articles and reviews that advance the understanding and treatment of microbial infections, including novel therapeutic approaches, drug targets, mechanisms of action, and delivery systems.

Guest Editor

Dr. Sara Consalvi

Department of Life Sciences, Health and Health Professions, Link Campus University, Via del Casale di San Pio V, 44, 00165 Rome, Italy

Deadline for manuscript submissions

30 September 2025



Future Pharmacology

an Open Access Journal
by MDPI

Impact Factor 2.7



mdpi.com/si/239192

Future Pharmacology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
future-
pharmacology@mdpi.com

[mdpi.com/journal/
futurepharmacol](https://mdpi.com/journal/futurepharmacol)





Future Pharmacology

an Open Access Journal
by MDPI

Impact Factor 2.7



[mdpi.com/journal/
futurepharmacol](https://mdpi.com/journal/futurepharmacol)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Fabrizio Schifano

Psychopharmacology, Drug Misuse and Novel Psychoactive
Substances Research Unit, School of Life and Medical Sciences,
University of Hertfordshire, Hertfordshire AL10 9AB, UK

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), EBSCO, and other
databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) Rapid Publication:
manuscripts are peer-reviewed and a first decision is
provided to authors approximately 21.8 days after
submission; acceptance to publication is undertaken in 4.7
days (median values for papers published in this journal in
the first half of 2025).